Alan C. Yeung, MD

Country USA
Specialty Interventional Cardiologist
  1. Balloon Expandable Valves. New Understandings about Sizing, Positioning, and Repeating
  2. Overview of Cardiac Arrest During Structural Heart Intervention
  3. Optimal Valve Choice in Various TAVR: A Complex Equation to Select One
  4. Antithrombotic Strategy in PCI and AF Patients: Updated Strategy
  5. Many Many Stents: What Should I Select?
  6. Cerebral Protection During TAVR: Why and How?
  7. Expanding Indication of TAVR: Ongoing Trials and Expectations
  8. Sapien 3 THV with Future Coronary Access
  9. Case 1: Complex LM/Multivessel Disease - Hybrid Revascularization
  10. PCI, CABG, or Both: Current Status of Hybrid Coronary Revascularization
  11. Expert Case Review: PCI for Severely Calcified In-Stent Restenosis
  12. TAVR in Low Risk Patients
  13. Sapien 3 or Evolut R: Different Indications?
  14. MV and TV Intervention: Preparing for the Next Revolution
  15. TAVR: Advancing Your Skills: Beyond the Basics
  16. How to Manage Complication TAVR Case
  17. Updates on Antiplatelet Therapy in Cardiovascular Disease
  18. Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment
  19. Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR)
  20. Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials?
  21. MV and TV Repair - Current Status and Innovative Future
  22. TVT Registry
  23. TAVR Clinical Trials
  24. PVL: How to Prevent and How to Treat?
  25. Sizing Strategy and PVL Management: Most Experienced Strategy
  26. TAVR for Low Risk Patients: Interventionist\'s Viewpoint
  27. The Evolution of Mitral and Tricuspid Valve Interventions: What It Is? and Where It Needs to Go?
  28. Experience, Current Status and Future of BRS in U.S. Real-World
  29. Technical Lessons for TAVR; Expert Experience
  30. Award Tribute
  31. Comparative Outcomes of Contemporary DES; Are There Major Difference?
  32. Low Coronary Ostium with Narrow or Wide Sinus
  33. Early Discharge Check List to Be Minimalist
  34. Frailty Assessment and How to Define Futile TAVR
  35. Next Issue: How to Manage Failed Transcatheter Heart Valve
  36. Complete Revascularization- The Future Mode of Revascularization in STEMI?
  37. Balloon Expandable System
  38. New Transcatheter Heart Valves
  39. Edward Sapien: Transfemoral
  40. TAVI: Future Perspectives
  41. Edward Sapien
  42. Coronary Obstruction: Treatment and Prevention
  43. Myocardial Bridge: Incidental Finding or Clinical Pathology?
  44. Invited Case Presentation & Focus Review: Multi-vessel Intervention
  45. Mediate a Dispute: Summary
  46. Promus-Element Stent
  47. In-Stent Restenosis - Stop ISR: How to Treat DES-ISR?: Summary
  48. The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS
  49. Clinical Decision Making in Patients with Left Main Disease
  50. Use of OCT in Treating a LAD/Diagonal Bifurcation Lesion
  51. Is It Real? Cytochrome P450 Genetic Polymorphisms, Varying Response to Clopidogrel, and Link to Clinical Outcomes : Global Perspective
  52. How to Teach and Train Innovation: US Approach
  53. Experiences of 2nd Generation OCT in Assessment of Complex Coronary Lesions; Can It Give Us Additive Useful Information?
  54. Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis
  55. Optimizing the Role of New Anti-thrombotic Regimens in ACS - When, What and Why?
  56. Endothelial Dysfunction Associated with DES: How Important?
  57. New Technologies for Bifurcation: Main Vessel Centric vs Side-Branch Centric
  58. New Devices in Bifurcation Lesions: Do We Really Need One?
  59. Bifurcation Stenting: Implications of the Norfic Study
  60. What Makes Endeavor Different
  61. D2B: An Alliance for Quality
  62. TAXUS Real-World Experience from ARRIVE Registry
  63. Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms
  64. Systemic Therapy: Pharmacologic Approach or Cell/Gene Therapy
  65. Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials
  66. What Are the Proper End Points for DES Trials?
  67. IVUS in Complex PCI
  68. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization I: Antrin
  69. ABT 578 Drug-Eluting Stents II: Preclinical Observations and the Clinical Trial Strategy for the Abbott ZoMax Stent
  70. What Are The Proper End Points for DES Trial
  71. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA) Pilot Trial
  72. Percutaneous Bypass: Rebirth as Treatment for CTO
  73. Bifurcation Stenoses: Is There a Solution in Sight ?
  74. Brachytherapy vs DES: Is the Answer in yet ?